This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Woolf AD (2007) An update on glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 19: 370–375
van Staa TP et al. (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13: 777–787
Homik J et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database of Systematic Reviews 1999, Issue 1. Art. No.: CD001347. 10.1002/14651858.CD001347
Lane NE et al. (2000) Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 15: 944–951
Acknowledgements
The synopsis was written by Kathryn Senior, Freelance Medical Writer.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Woolf, A., Åkesson, K. Is teriparatide or alendronate the best treatment for glucocorticoid-induced osteoporosis?. Nat Rev Rheumatol 4, 236–237 (2008). https://doi.org/10.1038/ncprheum0769
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0769